Predicting Chemotherapy Benefit in Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score-Pathology-Clinical (RSPC) Tool


Predicting Chemotherapy Benefit in Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score-Pathology-Clinical (RSPC) Tool
Slides from a presentation at SABCS 2010 and comments from Clifford Hudis, MD at an RTP satellite symposium during SABCS 2010 (12/11/10)

Tang G et al. Comparing the prediction of treatment benefit in patients with node-negative, ER-positive breast cancer using the recurrence score and a new measure that integrates clinical and pathologic factors with the recurrence score. San Antonio Breast Cancer Symposium 2010;Abstract S4-9.

Dr Hudis is Chief of the Solid Tumor Division’s Breast Cancer Medicine Service in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and is Professor of Medicine at Weill Cornell Medical College in New York, New York.